Primary debulking surgery versus neoadjuvant chemotherapy in stage IV ovarian cancer

Annals of Surgical Oncology

Volumn 19, Issue 3, 2012, Pages 959-965

  Rauh Hain, J Alejandro ^a,b   Rodriguez, Noah ^b   Growdon, Whitfield B ^a   Goodman, A K ^a   Boruta II, David M ^a   Horowitz, Neil S ^b   Del Carmen, Marcela G ^a   Schorge, John O ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PLATINUM DERIVATIVE; TAXANE DERIVATIVE; ANTINEOPLASTIC AGENT;

ADULT; ARTICLE; CANCER CHEMOTHERAPY; CANCER STAGING; CANCER SURGERY; CYTOREDUCTIVE SURGERY; FEMALE; FOLLOW UP; HOSPITAL READMISSION; HUMAN; INTENSIVE CARE UNIT; KAPLAN MEIER METHOD; MAJOR CLINICAL STUDY; MORBIDITY; OVARY CANCER; OVERALL SURVIVAL; PEROPERATIVE COMPLICATION; POSTOPERATIVE CARE; POSTOPERATIVE COMPLICATION; PRIMARY DEBULKING SURGERY; PROGRESSION FREE SURVIVAL; RETROSPECTIVE STUDY; TREATMENT OUTCOME; ADJUVANT CHEMOTHERAPY; ADJUVANT THERAPY; COMPARATIVE STUDY; MIDDLE AGED; MORTALITY; NEOPLASM; OVARY TUMOR; PATHOLOGY; SURVIVAL RATE;

ANTINEOPLASTIC AGENTS; CHEMOTHERAPY, ADJUVANT; FEMALE; HUMANS; MIDDLE AGED; NEOADJUVANT THERAPY; NEOPLASMS, GLANDULAR AND EPITHELIAL; OVARIAN NEOPLASMS; SURVIVAL RATE;

EID: 84862302151     PISSN: 10689265     EISSN: 15344681     Source Type: Journal    
DOI: 10.1245/s10434-011-2100-x     Document Type: Article

References (34)

1. Sankaranarayanan R, Ferlay J. Worldwide burden of gynaecological cancer: the size of the problem. Best Pract Res Clin Obstet Gynaecol. 2006;20:207-25. (Pubitemid 43380597)
2. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics. CA Cancer J Clin. 2010;60:277-300.
3. Cannistra SA. Cancer of the ovary. N Engl J Med. 2004;351:2519-29.
4. Akahira JI, Yoshikawa H, Shimizu Y, Tsunematsu R, Hirakawa T, Kuramoto H, et al. Prognostic factors of stage IV epithelial ovarian cancer: a multicenter retrospective study. Gynecol Oncol. 2001;81:398-403. (Pubitemid 32494653)
5. Winter WE 3rd, Maxwell GL, Tian C, Sundborg MJ, Rose GS, Rose PG, et al. Tumor residual after surgical cytoreduction in prediction of clinical outcome in stage IV epithelial ovarian cancer: a Gynecologic Oncology Group Study. J Clin Oncol. 2008;26:83-9.
6. Morgan RJ Jr, Alvarez RD, Armstrong DK, Chen LM, Copeland L, Fowler J, et al. Ovarian cancer. Clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2006;4:912-39. (Pubitemid 44580192)
7. Vergote I, Tropé CG, Amant F, Kristensen GB, Ehlen T, Johnson N, et al. Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer. N Engl J Med. 2010;363:943-53.
8. WHO handbook for reporting results of cancer treatments. Publication 48. Geneva: World Health Organization; 1979.
9. Hou JY, Kelly MG, Yu H, McAlpine JN, Azodi M, Rutherford TJ, Schwartz PE. Neoadjuvant chemotherapy lessens surgical morbidity in advanced ovarian cancer and leads to improved survival in stage IV disease. Gynecol Oncol. 2007;105:211-7. (Pubitemid 46441463)
10. Eisenhauer EL, Abu-Rustum NR, Sonoda Y, Levine DA, Poynor EA, Aghajanian C, et al. The addition of extensive upper abdominal surgery to achieve optimal cytoreduction improves survival in patients with stages IIIC-IV epithelial ovarian cancer. Gynecol Oncol. 2006;103:1083-90. (Pubitemid 44821338)
11. Bristow RE, Tomacruz RS, Armstrong DK, Trimble EL, Montz FJ. Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a metaanalysis. J Clin Oncol. 2002;1;20:1248-59. (Pubitemid 34177431)
12. Chi DS, Franklin CC, Levine DA, Akselrod F, Sabbatini P, Jarnagin WR, et al. Improved optimal cytoreduction rates for stages IIIC and IV epithelial ovarian, fallopian tube, and primary peritoneal cancer: a change in surgical approach. Gynecol Oncol. 2004;94:650-4. (Pubitemid 39194456)
13. Aletti GD, Dowdy SC, Podratz KC, Cliby WA. Analysis of factors impacting operability in stage IV ovarian cancer: rationale use of a triage system. Gynecol Oncol. 2007;105:84-9. (Pubitemid 46441445)
14. Wimberger P, Wehling M, Lehmann N, Kimmig R, Schmalfeldr B, Burges A, et al. Influence of residual tumor on outcome in ovarian cancer patients with FIGO stage IV disease: an exploratory analysis of the AGO-OVAR (Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group). Ann Surg Oncol. 2010;17:1642-8.
15. Aletti GD, Podratz KC, Cliby WA, Gostout BS. Stage IV ovarian cancer: disease site-specific rationale for postoperative treatment. Gynecol Oncol. 2009;112:22-7.
16. Chi DS, Liao JB, Leon LF, Venkatraman ES, Hensley ML, Bhaskaran D, Hoskins WJ. Identification of prognostic factors in advanced epithelial ovarian carcinoma. Gynecol Oncol. 2001;82:532-7. (Pubitemid 32826455)
17. Bristow RE, Eisenhauer EL, Santillan A, Chi DS. Delaying the primary surgical effort for advanced ovarian cancer: a systematic review of neoadjuvant chemotherapy and interval cytoreduction. Gynecol Oncol. 2007;104:480-90. (Pubitemid 46135675)
18. Bristow RE, Chi DS. Platinum based neoadjuvant chemotherapy and interval cytoreduction for advance ovarian cancer: a metaanalysis. Gynecol Oncol. 2006;103:1070-6. (Pubitemid 44821335)
19. Baekelandt M. The potential role of neoadjuvant chemotherapy in advanced ovarian cancer. Int J Gynecol Cancer. 2003;13(Suppl2):163-8. (Pubitemid 38228759)
20. Chi DS, Schwartz PE. Cytoreduction vs. neoadjuvant chemotherapy for ovarian cancer. Gynecol Oncol. 2008;111:391-9.
21. Schwartz PE, Chambers JT, Makuch R. Neoadjuvant chemotherapy for advanced ovarian cancer. Gynecol Oncol. 1994;53:33-7. (Pubitemid 24136898)
22. van der Burg ME, van Lent M, Buyse M, Kobierska A, Colombo N, Favalli G, et al. The effect of debulking surgery after induction chemotherapy on the prognosis in advanced epithelial ovarian cancer. N Engl J Med. 1995;332:629-34.
23. Vergote I, van Gorp T, Amant F, Neven P, Berteloot P. Neoadjuvant chemotherapy for ovarian cancer. Oncology. 2005;19:1615-22. (Pubitemid 46511211)
24. Baekelandt M. The potential role of neoadjuvant chemotherapy in advanced ovarian cancer. Int J Gynecol Cancer. 2003;13(Suppl 2):163-8. (Pubitemid 38228759)
25. Surwit E, Childers J, Atlas I. Neoadjuvant chemotherapy for advanced ovarian cancer. Int J Gynecol Cancer. 1996;6:356-66.
26. Vergote I, De Wever I, Tjalma W, Van Gramberen M, Decloedt J, van Dam P. Neoadjuvant chemotherapy or primary debulking surgery in advanced ovarian carcinoma: a retrospective analysis of 285 patients. Gynecol Oncol. 1998;71:431-6. (Pubitemid 29022333)
27. Ansquer Y, Leblanc E, Clough K, Morice P, Dauplat J, Mathevet P, et al. Neoadjuvant chemotherapy for unresectable ovarian carcinoma. Cancer. 2001;91:2329-34. (Pubitemid 32552819)
28. Kang S, Nam BH. Does neoadjuvant chemotherapy increase optimal cytoreduction rate in advanced ovarian cancer? Metaanalysis of 21 studies. Ann Surg Oncol. 2009;16:2315-20.
29. Tangjitgamol S, Manusirivithaya S, Laopaiboon M, Lumbiganon P, Bryant A. Interval debulking surgery for advanced epithelial ovarian cancer. Cochrane Database Syst Rev. 2010;(10):CD006014.
30. Morrison J, Swanton A, Collins S, Kehoe S. Chemotherapy versus surgery for initial treatment in advanced ovarian epithelial cancer. Cochrane Database Syst Rev. 2007;(4):CD005343.
31. Schwartz PE, Rutherford TJ, Chambers JT, Kohorn EI, Thiel RP. Neoadjuvant chemotherapy for advanced ovarian cancer: longterm survival. Gynecol Oncol. 1999;72:93-9. (Pubitemid 29045454)
32. Hegazy MA, El-Shafei MA, Setit AE, Amin MA, Kotb SZ, El Shafei MA, Yousef TF, et al. Neoadjuvant chemotherapy versus primary surgery in advanced ovarian carcinoma. World J Surg Oncol. 2005;31:57.
33. Loizzi V, Rossi C, Cormio G, Cazzolla A, Altomare D, Selvaggi L. Clinical features of hepatic metastasis in patients with ovarian cancer. Int J Gynecol Cancer. 2005;15:26-31. (Pubitemid 40194329)
34. Bristow RE, Montz FJ, Lagasse LD, Leuchter RS, Karlan BY. Survival impact of surgical cytoreduction in stage IV epithelial ovarian cancer. Gynecol Oncol. 1999;72:278-87. (Pubitemid 29118182)